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doi:10.1016/j.jtcvs.2007.12.055Objective: Remote ischemic preconditioning is known to elicit production of a blood-
borne cardioprotective factor that is infarct sparing in models of ischemia–reperfusion
injury and myocardial damage reducing after cardiopulmonary bypass in human sub-
jects. The mechanism of protection remains incompletely understood. In this study,
we examined effects on mitochondrial structure and function in a noninfarct model
of cardioplegic arrest.
Methods: Explanted neonatal rabbit hearts were mounted in a Langendorff prepara-
tion and perfused with dialysate of blood taken from sham-treated or remotely precon-
ditioned rabbits. Each heart was subsequently subjected to 1-hour cardioplegic arrest
and 30-minute reperfusion periods, during which hemodynamic responses were mea-
sured. Mitochondria were isolated for structural and functional measurements.
Results: Relative to hearts with sham-treated dialysate, myocardial performance (sys-
tolic pressure, maximum positive and negative first derivatives of left ventricular pres-
sure, and left ventricular end-diastolic pressure) was better preserved with dialysate
from preconditioned rabbits. Similarly, mitochondria isolated from hearts with dialy-
sate from preconditioned rabbits showed preserved respiration at complex I and IV in
the electron transport chain (P, .01 and P, .05, respectively). Mitochondrial outer
membrane integrity was also preserved, with diminished sensitivity of mitochondrial
respiration to exogenous cytochrome c (P , .01) and less cytosolic diffusion of cy-
tochrome c (P , .01). Mitochondrial resistance to calcium-mediated mitochondrial
permeability transition pore opening was not affected.
Conclusion: The cardioprotective factor in plasma dialysate after remote precondi-
tioning preserves mitochondrial structure and function in a noninfarct cardioplegic
arrest model. This protection is associated with preservation of global myocardial
performance.
I
schemic preconditioning is a phenomenon in which brief antecedent ischemic pe-
riods render tissue more resistant to subsequent prolonged and potentially lethal
ischemic insults. First described by Murry and colleagues,1 preconditioning is
now recognized as one of the most potent innate protective mechanisms against ische-
mia–reperfusion injury. Although preconditioning-mediated myocardial protection is
well documented in preclinical experimental models, there have been relatively few
descriptions of its clinical use, reflecting the practical difficulties in inducing local
tissue ischemia before an ischemic insult.2-4
Unlike classic ischemic preconditioning, which requires ischemia of the target
organ, remote ischemic preconditioning (rIPC) uses ischemia of a distant organ to
The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 2 335
Surgery for Congenital Heart Disease Wang et al
CH
DAbbreviations and Acronyms
KHB 5 Krebs–Henseleit
KATP 5 adenosine triphosphate–dependent potassium
LV 5 left ventricle
MPT 5 mitochondrial permeability transition
rIPC 5 remote ischemic preconditioning
confer the protection against myocardial infarction.5-9 Al-
though the mechanisms of rIPC-derived cardioprotection
have not yet been determined,10,11 recent studies by our
group and others have suggested that a transferable blood-
borne factor confers rIPC-induced cardioprotection.12-14 Fur-
thermore, we have recently shown that rIPC reduces markers
of myocardial damage in infants and children undergoing
cardiac surgery with cardioplegic arrest.14
Myocardial infarction is uncommon after cardioplegic
arrest in the neonate. Nonetheless, cardioplegic arrest is asso-
ciated with a constellation of structural and functional alter-
ations in mitochondria15,16 that may play an important role
in global cardiac performance.17 In addition to energy pro-
duction, the mitochondria also play a central role in modulat-
ing the myocellular response to ischemic injury, such as
either temporary cellular dysfunction or cell death.18 Mito-
chondria are therefore likely to be downstream participants
in the protective effects of rIPC.
Numerous factors have been to shown to be cardioprotec-
tive, including eicosotrianoic acids, adipokines, cytokines,
bradykinins, and enkephalins. It is not clear which (if any)
of these factors are responsible for the infarct-sparing effects
seen after rIPC. We have shown, however, that dialysate
from plasma contains one or more cardioprotective factors
with similar potency to plasma from remotely preconditioned
rabbits.19 In the absence of a clearly identified protective fac-
tor, the dialysate from plasma of preconditioned animals thus
represents a convenient source of the cardioprotective factor
associated with remote preconditioning. Our study provides
evidence that a blood-borne cardioprotective factor present
in dialysate of plasma from remotely preconditioned rabbits
preserves mitochondrial structure and function after cardio-
plegic arrest. Furthermore, this mitochondrial protection is
associated with preservation of myocardial performance.
Materials and Methods
Plasma Dialysate Preparation
The rIPC-treated dialysate was isolated according to the following
protocol. New Zealand adult rabbits (3.5–4.0 kg) were anesthetized
with pentobarbital. The left internal carotid artery was cannulated
with a blood collection tube. The rIPC was induced with four cycles
of hind limb ischemia (by cuff) and reperfusion (5 minutes each).
Absence of distal pulse in the limb during ischemia was confirmed
by pulse oximetry. At the end of the experiment, rabbits were hepa-
rinized (150 units/kg intravenously) and blood (approximately 100336 The Journal of Thoracic and Cardiovascular Surgery c AumL) was withdrawn. After centrifugation of the blood at 3000 rpm
for 20 minutes, the supernatant (approximately 50 mL plasma)
was transferred into a dialysis tubing, which was submerged in 1 L
of Krebs–Henseleit buffer (KHB; 118-mmol/L sodium chloride,
25-mmol/L sodium hydrogen carbonate, 1.2-mmol/L monobasic po-
tassium phosphate, 4.7-mmol/L potassium chloride, 1.2-mmol/L
magnesium sulfate, 1.8-mmol/L calcium chloride, and 11-mmol/L
glucose) with mild stirring overnight. The dialysate blended with
KHB was used for Langendorff perfusion buffer. Sham-treated dial-
ysate was created according to an identical protocol in rabbits that
did not undergo the repetitive limb ischemia.
Experimental Model
Neonatal New Zealand white rabbits (age 6 days, weight 150–200 g)
were anesthetized with pentobarbital (50 mg/kg intraperitoneally),
anticoagulated with heparin (1000 units/kg intraperitoneally), and
mechanically ventilated. The aorta was cannulated, and the heart
was retrogradely perfused in situ to avoid ischemia. The heart was
then excised, mounted on a Langendorff apparatus, and perfused
with KHB with either sham-treated or rIPC-treated dialysate at a per-
fusion pressure of 75 mm Hg. Perfusate was filtered with a 2-mm fil-
ter (Invitrogen Corporation, Carlsbad, Calif] and equilibrated with
95% oxygen and 5% carbon dioxide, adjusted to a pH of 7.35 to 7.4.
All animals received humane care and treatment in accordance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’
(www.nap.edu/catalog/5140.html).
Experimental Protocol
After being perfused for 20 minutes with KHB with plasma dialy-
sate from rIPC-treated rabbits (n 5 6) or from sham-treated rabbits
(n 5 6), hearts were subjected to cardioplegic arrest for 1 hour at
37C (70-mL/kg Plegisol; Hospira, Inc, Lake Forest, Ill). The hearts
were then reperfused with the respective dialysate-blended KHB for
another 30 minutes and then removed.
For mitochondrial oxygen consumption measurements, myocar-
dium was immediately fractionated as previously described.17 Fresh
mitochondrial fractions were used for oxygen consumption mea-
surements. Mitochondrial purity was confirmed by inspection of
randomly chosen electron micrographs. In a second set of animals
(n 5 4 per group), left ventricles (LVs) were imbedded in optimal
cutting temperature compound, frozen in liquid nitrogen, and stored
at 280C for apoptosis assessment and fluorescence immunohisto-
chemical imaging.
LV Functional Assessment
Isovolumetric LV performance was evaluated with a water-filled
balloon connected to a force transducer (MLT844; ADInstruments,
Inc, Colorado Springs, Colo) inserted in the LV across the mitral
valve. The volume of the water-filled balloon was determined at
a constant physiologic end-diastolic pressure in a range of 0 to
5 mm Hg, and its volume was kept consistent throughout the entire
experiment. LV performance was assessed by measurements of LV
systolic pressure, LV end-diastolic pressure, and positive and nega-
tive first derivatives of LV pressure. Heart rate was detected with
a small disk electron probe (Harvard Apparatus, Inc, Holliston,
Mass) connected to an electrocardiographic amplifier (ML136;
ADInstruments). Analog data were digitized and analyzed with soft-
ware (chart IV; ADInstruments).gust 2008
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The LV was used for mitochondrial isolation by differential centri-
fugation as described.17 Briefly, the LV was finely minced in 5 mL
ice-cold mitochondrial isolation buffer (5-mmol/L 3-[N-morpholi-
no]propanesulfonic acid, 2-mol/L ethylene glycol bis-2-aminoethyl
ether-N, N0, N00, n0-tetraacetic acid, 70-mmol/L sucrose, 220-mmol/
L mannitol, 1-mmol/L dithiothreitol, 17-mg/mL phenylmethylsul-
fonyl fluoride, 8-mg/mL aprotinin, and 2-mg/mL leupeptin, pH
7.2) with 0.1% bovine serum albumin and was homogenized on
ice with a blade homogenizer. After 5 cycles (5 minutes each) of
low spin (700g), the supernatant was transferred to a new tube
and centrifuged at 8000g for 10 minutes. The pellet was resuspended
in 10 mL mitochondrial isolation buffer with 0.1% bovine serum al-
bumin and centrifuged at 8000g for another 10 minutes. The final
pellet was suspended in mitochondrial isolation buffer without bo-
vine serum albumin for mitochondrial oxygen consumption mea-
surements.
Clark-Type Electrode Oxygen Consumption
Measurement
Mitochondrial complex I, II, and IV respiration was measured by the
method of Ricci and associates20 with a Clark-type oxygen electrode
(Instech Laboratories, Inc, Plymouth Meeting, Pa). Oxygen con-
sumption was measured in the presence of sequential administration
of substrates and inhibitors (glutamate and malate for complex I,
rotenone and succinate for complex II, and antimycin, N, N, N0N0-
tetramethyl-p-phenylenediamine, and ascorbate for complex IV)
added in the following order and final concentrations: 2.5-mmol/L
glutamate, 2.5-mmol/L malate, 2-mmol/L adenosine diphosphate,
2-mmol/L rotenone, 5-mmol/L succinate, 1-mmol/L antimycin A,
1-mmol/L ascorbate, and 0.4-mmol/LN, N, N0N0-tetramethyl-p-phe-
nylenediamine. Respiration rates are expressed as micromoles of
oxygen per minute per milligram of mitochondrial protein. All the
substrates and inhibitors were purchased from Sigma-Aldrich
(Sigma-Aldrich Corporation, St Louis, Mo). The voltage signal
was amplified and digitized by a computer-supported PowerLab
ADInstruments System (ADInstruments Pty Ltd, Castle Hill,
Australia).
Outer Mitochondrial Membrane Permeability
The integrity of the outer membrane was assessed as previously de-
scribed by measuring isolated mitochondrial oxygen consumption
after administration of exogenous cytochrome C (10 mmol/L) into
the respiratory chamber during the measurement of ascorbate-driven
mitochondrial respiration (complex IV)21. The subsequent increase
in complex IV activity reflects permeabilization of the outer mito-
chondrial membrane.22
Fluorescent Immunohistochemical and Confocal
Imaging
Optimal cutting temperature compound–embedded transverse ven-
tricular slices were cut into 5-mm serial sections and fixed in acetone;
after blocking, rabbit monoclonal anti–cytochrome c oxidase IV
(1:250; Cell Signaling Technology, Inc, Beverly, Mass) was used.
Sections were incubated with secondary antibody (Cy 2 reactive
dye (green)3-conjugated donkey anti–rabbit Ig G, 1:500 (Cy is
the trademark of Auershan Biosciences Ltd. NJ); Jackson Immu-
noResearch Laboratories, Inc, West Grove, Pa). Mouse monoclonalThe Journal of Thoanti–cytochrome c (1:200; BD Pharmingen, San Diego, Calif) was
used as the primary antibody for cytochrome c staining. Sections
were immersed in secondary antibody (Cy 3 reactive dye
(red)2-conjugated donkey anti–mouse Ig G, 1:200; Jackson Im-
munoResearch Laboratories). The images from at least three differ-
ent sections were acquired at 643 with a Zeiss LSM510
Multiphoton Laser Scanning Confocal Microscope (Carl Zeiss,
Oberkochen, Germany) with the same pinhole setting, pixel format
(1024 3 1024), and scanning data depth (0.8 mm). Double fluores-
cence for green and red channels was imaged with excitation of Ar-
gon-HeNe1 at the wavelengths 488 and 530 nm. Fifty high-power
fields from each animal were analyzed with imaging processing
software (Volocity 3.0; Improvision Inc, Waltham, Mass). High-in-
tensity red and green (.551 voxels) were each regarded as specific
immunoreactive signals. The red signal (cytochrome c oxidase IV)
was set as a reference, and the contribution of the green signal (cy-
tochrome c) to the colocalization of both signals was quantified as
the overlap coefficient and used to compare the diffusion of cyto-
chrome c staining between groups.23
Mitochondrial Calcium Tolerance: Mitochondrial
Permeability Transition Pore Opening Threshold
Experiments
Mitochondrial calcium tolerance was determined by calcium ion–
induced swelling of isolated cardiac mitochondria.24 Administration
of exogenous calcium results in mitochondrial swelling, which is
measured spectrophotometrically as a reduction in absorbance at
520 nm. Isolated cardiac mitochondria were resuspended in a swell-
ing buffer to a final protein concentration of 0.22 mg/mL. Calcium
chloride (100 mmol/L) was added, and the percentage decline of ab-
sorbance at 520 nm was continuously recorded. Cyclosporine (INN
cyclosporin), an inhibitor of mitochondrial permeability transition
(MPT) pore opening,24 was used as a control. We have previously
demonstrated that cyclosporine is a potent inhibitor of MPT pore
opening after cardioplegic arrest.16
Statistics
Data are expressed as mean6 SEM. Group comparisons were made
with the Fisher least significant difference analysis of variance. A
Tukey test was used for post hoc comparison.
Results
Hemodynamic Responses
There was no significant difference in heart rate between
groups with sham-treated dialysate and those with rIPC-
treated dialysate throughout the reperfusion period (Table 1).
The LV end-diastolic pressure was significantly greater at 5,
15, and 30 minutes after reperfusion in hearts with sham-
treated dialysate relative to rIPC-treated dialysate. LV sys-
tolic pressure and positive and negative maximum first deriv-
atives of LV pressure were significantly better preserved in
hearts with rIPC-treated dialysate relative to those with
sham-treated dialysate.
Mitochondrial Oxygen Consumption
Deficits in state 3 mitochondrial respirations at complex I
and IV were greater in mitochondria from animals withracic and Cardiovascular Surgery c Volume 136, Number 2 337
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DTABLE 1. Hemodynamics in hearts perfused with sham-treated dialysate and remote ischemic preconditioning–treated
dialysate
Reperfusion
Baseline 5 min 15 min 30 min
Variables Sham rIPC Sham rIPC Sham rIPC Sham rIPC
Heart rate (beats/min) 216 6 8 210 6 4.5 203 6 10.9 210 6 4.7 206 6 8.6 215 6 4.5 201 6 9.6 206 6 4.2
LVP 100 100 78.8 6 2.9 87.8 6 1.8* 84.1 6 1.9 93.8 6 1.1* 88.4 6 1.5 96.8 6 1.2*
LVEDP (mm Hg) 2.1 6 0.12 2.2 6 0.11 12.6 6 1.7 7.8 6 1.2* 8.9 6 0.7 4.74 6 0.8* 7.03 6 0.26 3.12 6 0.4*
1dP/dT (D%) 100 100 64.5 6 4.3 82.7 6 3.2* 78.5 6 2.5 94.6 6 1.1* 86.2 6 1.5 96.3 6 0.9*
2dP/dT (D%) 100 100 62.2 6 3.7 79 6 2.6* 76.1 6 2.7 91.52 6 2.2* 82.4 6 2.1 94.5 6 1.0*
Values are mean 6 SEM, n 5 6 per group. rIPC, Remote ischemic preconditioning; LVP, left ventricle pressure; LVEDP, left ventricle end diastolic pressure;
1dP/dt, positive first derivative of left ventricular pressure; 2dP/dt, negative first derivative of left ventricular pressure. *P , .01 versus sham-treated
dialysate.sham-treated dialysate than those with rIPC-treated dialysate.
These differences remained significant after normalization of
state 3 to state 2 mitochondrial respiration rates (Table 2 and
Figure 1). Complex II oxygen consumption rates were not
different. Baseline isolated mitochondrial oxygen consump-
tion was assessed during basal state 2 respiration for mito-
chondrial complexes I, II, and IV and was not different
between groups, suggesting that there was no significant
mitochondrial injury after fractionation.25
Mitochondrial Outer Membrane Integrity
Administration of exogenous cytochrome c both measured
the oxygen consumption of isolated mitochondria and also
assessed the integrity of the outer mitochondrial membrane.
Cardioplegic arrest resulted in a deficit in complex IV state 3
respiration in mitochondria with sham-treated dialysate. This
deficit was minimized with rIPC-treated dialysate (Figure 2,
B). Administration of exogenous cytochrome c resulted in
a more than 3-fold increase in complex IV state 3 respiration
in mitochondria with sham-treated dialysate (indicating
permeabilization of the outer mitochondrial membrane),
whereas there was a minimal increase in the mitochondria
with rIPC-treated dialysate (indicating maintenance of outer
mitochondrial membrane integrity, 3.46 6 0.33 vs 1.17 6
0.22, P , .01, Figure 2, C). The deficit in complex IV
activity in mitochondria with sham-treated dialysate was
fully reversible with addition of exogenous cytochrome c,suggesting that permeabilization and loss of cytochrome c
may have important consequences in terms of mitochondrial
performance.
Mitochondrial Cytochrome c Release
Merged images of cytochrome c oxidase IV and cytochrome
c staining of tissue sections from hearts perfused with sham-
treated dialysate show subjectively decreased colocalization
relative to myocardium perfused with rIPC-treated dialysate
(Figure 3, A). Decreased colocalization in the myocardium
with sham-treated dialysate is suggestive of mitochondrial re-
lease of cytochrome c into the cytoplasm, whereas preserva-
tion of the colocalization is consistent with maintenance of
outer mitochondrial membrane integrity. The overlap quanti-
fication coefficient was greater in the myocardium with rIPC-
treated dialysate than in the myocardium with sham-treated
dialysate (1.46 6 0.03 vs 1.21 6 0.05 arbitrary units, P ,
.01), providing objective evidence of rIPC-treated dialysate’s
association with preservation of outer mitochondrial mem-
brane integrity.
MPT Pore Opening
The amount of calcium ion required to trigger calcium-in-
duced MPT pore opening was not different between mito-
chondria isolated from myocardium perfused with sham-
treated dialysate versus rIPC-treated dialysate, suggesting
that the rIPC-treated dialysate did not directly promoteTABLE 2. Isolated mitochondrial oxygen consumption
Complex I Complex II Complex IV
Sham rIPC Sham rIPC Sham rIPC
State 2 0.588 6 0.018 0.585 6 0.022 0.588 6 0.018 0.585 6 0.022 0.588 6 0.018 0.585 6 0.022
State 3 3.343 6 0.018 6.133 6 0.701* 2.727 6 0.235 3.132 6 0.27 6.937 6 0.396 8.795 6 0.63y
Ratio 3/2 5.669 6 0.6 10.452 6 1.024* 4.619 6 0.358 5.36 6 0.38 11.79 6 0.643 15.09 6 1.07y
Values are mean6 SEM in micromoles oxygen per minute per milligram mitochondrial protein, n5 6 per group. rIPC, Remote ischemic preconditioning. *P,
.01 versus sham-treated dialysate. yP , .05 versus sham-treated dialysate.
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DFigure 1. A, Representative traces of
real-time mitochondrial oxygen con-
sumption (Mito) including complex I
(Glu1Mal [glutamine and maleate]), II
(Rotenone and Succinate), and IV (Anti-
mycin and Asco1TMPD [ascorbate and
N, N, N 0N 0-tetramethyl-p-phenylenedi-
amine]). rIPC, Remote ischemic precon-
ditioning; ADP, adenosine diphosphate.
B and C, Comparison of state 3 and state
3/2 ratios for complex I, II, and IV respi-
ration. Asterisk indicates
P < .05 versus sham-treated dialysate;
double asterisk indicates P< .01 versus
sham-treated dialysate. rIPC, Remote is-
chemic preconditioning.MPT pore opening (Figure 4). Calcium ion–mediated MPT
pore opening in both groups, however, could be blocked
with cyclosporine, an inhibitor of MPT pore opening.
Discussion
We have recently reported a clinical benefit of rIPC in chil-
dren subjected to cardioplegic arrest during cardiac sur-
gery.14 The cellular mechanisms of this benefit remain
incompletely understood. Nonetheless, it is clear that tran-
sient ischemia liberates at least one transferable blood-borne
factor that confers remote protection against myocardial
infarction,10,12 and dialysis of plasma from preconditionedanimals isolates an equipotent dialysate with infarct-sparing
effects in isolated heart preparations.19
In contrast to myocardial infarction, typical pathologic
changes after cardioplegic arrest include a constellation of
apoptosis-related alterations in mitochondrial structure and
function, such as the permeabilization of the outer mitochon-
drial membrane, cytochrome c release, and deficiency of
electron transport.15-17 Because mitochondria are thought to
play crucial roles in mediating both cardiac function and car-
diomyocyte cell death,18,26 and rIPC is a reliable method for
protecting myocardium against ischemia and reperfusion–
induced cell death,7,8 we hypothesized that rIPC preventsFigure 2. A, Mitochondrial (Mito) com-
plex IV oxygen consumption before and
after addition of exogenous cytochrome
c to mitochondria isolated from myocar-
dium with sham-treated dialysate and
with remote ischemic preconditioning
(rIPC)–treated dialysate. Boost in com-
plex IVoxygen consumption in response
to added cytochrome c is demonstrated
by steeper slope in oxygen consumption
(indicated by arrows within circles).
Glu1Mal, Glutamine and maleate; As-
co1TMPD, ascorbate and N, N, N 0N 0-
tetramethyl-p-phenylenediamine. B,
Complex IV oxygen consumption before
and after addition of exogenous cyto-
chrome c. Asterisk indicates P < .05
versus sham-treated dialysate. rIPC,
Remote ischemic preconditioning. C,
Increase in complex IV activity after
addition of exogenous cytochrome c.
Double asterisk indicates P< .01 versus
sham-treated dialysate.
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Figure 3. A, Immunofluorescence of cytochrome c oxidase IV (COX IV) and cytochrome c in myocardium from myo-
cardium with sham-treated dialysate and with remote ischemic preconditioning (rIPC)–treated dialysate. In each
panel, cytochrome c oxidase IV (mitochondria) is stained red, cytochrome c is stained green, and merged images
are shown. Superimposition of red and green staining results in brownish color that suggests retention of cyto-
chrome c in remote ischemic preconditioning–treated dialysate. Fine, diffuse green staining can be seen in merged
images of myocardium with sham-treated dialysate, suggesting mitochondrial release of cytochrome c. Scatter
plots display intensity range of red and green pixels in merged images of both myocardium groups, as well as var-
ious degrees of colocalization, as shown in orange and yellow. B, Quantification of overlap coefficient (Kx-green) in
merged images. Double asterisk indicates P< .01 versus sham-treated dialysate. rIPC, Remote ischemic precondi-
tioning.postcardioplegia myocardial dysfunction through preserva-
tion of mitochondrial structure and function. This study dem-
onstrates that rIPC-treated dialysate protects against loss of
outer mitochondrial membrane integrity and subsequent def-
icits in electron transport and that this protection is correlated
with preservation of global myocardial performance.
Laboratory reports evaluating preconditioning typically
use reduction in infarct size as a primary end point. Although
a reduction in infarct size is of potential clinical importance in
coronary revascularization, it does not necessarily confer
a clinical benefit in settings where ischemia–reperfusion340 The Journal of Thoracic and Cardiovascular Surgery c Auginjury is not associated with infarction (eg, protected ischemia
during cardioplegic arrest). This study demonstrates that the
rIPC-related cardioprotective factor confers benefits extend-
ing beyond reduction of infarct size and including mitochon-
drial preservation and augmentation of postcardioplegic
myocardial performance.
Our group previously demonstrated dependence of the
rIPC cardioprotective factor on mitochondrial adenosine
triphosphate–dependent potassium (KATP) channels in an in-
farct-reduction model.12 With a model of cardioplegic arrest,
we have also demonstrated that diazoxide, a mitochondrialust 2008
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DKATP opener, preserves mitochondrial structure and func-
tion after cardioplegic arrest,15 with a pattern of protection
(preservation of mitochondrial integrity and function of
complex I) that is strikingly similar to that seen in this
study. Consequently, this study is consistent with a role for
the mitochondrial KATP channel as a mediator of rIPC
protection.
It is important to note, however, that the MPT pore is also
an important mediator of myocardial ischemic injury and ini-
tiation of apoptosis,27,28 and pharmacologic inhibition of
MPT pore opening is associated with myocardial protection
against ischemia–reperfusion injury.29,30 We have previously
demonstrated that cyclosporine, which blocks MPT pore
opening, can ameliorate deficits in mitochondrial integrity
and electron transport after neonatal cardioplegic arrest.16 In
this study, calcium-induced MPT pore opening was not al-
tered with rIPC-treated dialysate but could be blocked with
cyclosporine, suggesting that the mechanism of rIPC-medi-
ated cardioprotection in the model used in this study is not me-
diated directly through MPT pore opening. The MPT pore and
the mitochondrial KATP channel thus may be important but
distinct sequential mediators in mitochondrial preservation
after cardioplegic arrest. The MPT pore may be involved in
a secondary amplification loop of a mitochondrial KATP
channel–mediated signal that participates in subsequent
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Figure 4. Calcium ion (Ca21)–induced swelling, index of mito-
chondrial permeability transition pore opening, was measured
as decrease in absorbance at 520 nm (DA520nm). Representative
traces from six independent experiments are shown for cardiac
mitochondria isolated from myocardium with sham-treated dialy-
sate and remote ischemic preconditioning (rIPC)–treated dialy-
sate. Mitochondrial permeability transition pore inhibitor
cyclosporine (CsA, 0.2 mmol/L), abolished effects on absorption
in both groups. Decreases in absorption in sham-treated and
remote ischemic preconditioning–treated dialysate groups were
nearly identical.The Journal of Thorpermeabilization not evident in the current in vitro assessment
of calcium-induced mitochondrial permeabilization.30
At present, the identity of the cardioprotective factor re-
mains elusive. Lang and coworkers5 used a proteomics ap-
proach and were unable to identify a cardioprotective factor
larger than 8 kDa. Interestingly, albumin fragments and liver
regeneration–related protein (LRRG03) were noted to be up-
regulated, and the potential for a small protein (,8 kDa) was
not excluded. Other characteristics of the cardioprotective
factor include hydrophobicity and activity through a protein
kinase C–related pathway.31 Other groups have demon-
strated that the protective factor is dependent on KATP chan-
nels32 or opioid receptors.33 Ongoing efforts to identify and
characterize the cardioprotective factor will be required to
clarify these protective mechanisms.
Conclusions
In addition to infarct-sparing effects, rIPC is associated with
release of a blood-borne cardioprotective factor that main-
tains mitochondrial structure and function and preserves
global myocardial performance after neonatal cardioplegic
arrest. Characterization and identification of the rIPC cardio-
protective factor will foster recruitment of innate protective
mechanisms to improve myocardial preservation.
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